A Review on The Role of VEGF in Tamoxifen Resistance
- PMID: 30207246
- DOI: 10.2174/1871520618666180911142259
A Review on The Role of VEGF in Tamoxifen Resistance
Abstract
Background: Certain molecular deviations can lead to the development of breast cancer. For instance, estrogen and estrogen receptors play a significant role in inducing tumor proliferation. However, the efficacy of endocrine therapy through the administration of anti-estrogen drugs, such as Tamoxifen, is challenged by acquired resistance.
Methods: Relevant articles were retrieved from Medline and google scholar. All were screened to select the ones discussing the molecular mechanisms of angiogenesis and Tamoxifen resistance. The molecular interactions contributing in the resistant network were studied from the eligible articles.
Results: Tamoxifen resistance occurs as a consequence of over-activated signal transduction pathways such as RTK s dependent cascades. It has been shown that microvessel count was greater in Tamoxifen resistant tissues than in responsive ones.
Conclusion: In this review, the interaction between estrogen, Tamoxifen, VEGF, and VEGF receptors (VEGFRs) in Tamoxifen resistant cells has been discussed. VEGF and estrogen-independent growth cascades, especially MAPK have a positive feedback loop in Tamoxifen resistant cells. It has been proposed that over-activated pathways in Tamoxifen resistant cells induce pin1 mediated VEGF over-expression, which in turn result in enhanced activation of MAPK.
Keywords: Angiogenesis; MAPK; VEGF; breast cancer; estrogen; molecular network; tamoxifen resistance..
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Similar articles
-
An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells.Mol Cancer Res. 2008 Oct;6(10):1630-8. doi: 10.1158/1541-7786.MCR-07-2172. Mol Cancer Res. 2008. PMID: 18922978
-
Stemness Phenotype in Tamoxifen Resistant Breast Cancer Cells May be Induced by Interactions Between Receptor Tyrosine Kinases and ERα-66.Recent Pat Anticancer Drug Discov. 2018;13(3):302-307. doi: 10.2174/1574892813666180305164634. Recent Pat Anticancer Drug Discov. 2018. PMID: 29512469 Review.
-
Estrogen can restore Tamoxifen sensitivity in breast cancer cells amidst the complex network of resistance.Biomed Pharmacother. 2017 Sep;93:1320-1325. doi: 10.1016/j.biopha.2017.07.057. Epub 2017 Jul 23. Biomed Pharmacother. 2017. PMID: 28747013 Review.
-
Amurensin G inhibits angiogenesis and tumor growth of tamoxifen-resistant breast cancer via Pin1 inhibition.Food Chem Toxicol. 2012 Oct;50(10):3625-34. doi: 10.1016/j.fct.2012.07.027. Epub 2012 Jul 27. Food Chem Toxicol. 2012. PMID: 22842120
-
Mechanisms of FGFR3 actions in endocrine resistant breast cancer.Int J Cancer. 2012 Jun 15;130(12):2857-66. doi: 10.1002/ijc.26304. Epub 2011 Aug 29. Int J Cancer. 2012. PMID: 21792889
Cited by
-
Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer.Front Pharmacol. 2021 Mar 15;12:628690. doi: 10.3389/fphar.2021.628690. eCollection 2021. Front Pharmacol. 2021. PMID: 33790792 Free PMC article. Review.
-
Design, synthesis and biological evaluation of a new thieno[2,3-d]pyrimidine-based urea derivative with potential antitumor activity against tamoxifen sensitive and resistant breast cancer cell lines.J Enzyme Inhib Med Chem. 2020 Dec;35(1):1641-1656. doi: 10.1080/14756366.2020.1804383. J Enzyme Inhib Med Chem. 2020. PMID: 32781854 Free PMC article.
-
Knockdown of ATG4A inhibits breast cancer progression and promotes tamoxifen chemosensitivity by suppressing autophagy.Mol Med Rep. 2022 Mar;25(3):101. doi: 10.3892/mmr.2022.12617. Epub 2022 Jan 28. Mol Med Rep. 2022. PMID: 35088889 Free PMC article.
-
Crosstalk between MUC1 and VEGF in angiogenesis and metastasis: a review highlighting roles of the MUC1 with an emphasis on metastatic and angiogenic signaling.Cancer Cell Int. 2021 Apr 9;21(1):200. doi: 10.1186/s12935-021-01899-8. Cancer Cell Int. 2021. PMID: 33836774 Free PMC article. Review.
-
Phase II study of apatinib plus exemestane in estrogen receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer.Cancer Biol Ther. 2023 Dec 31;24(1):2265055. doi: 10.1080/15384047.2023.2265055. Epub 2023 Oct 13. Cancer Biol Ther. 2023. PMID: 37831547 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous